Avidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 1,965 Shares of Stock

Avidity Biosciences, Inc. (NASDAQ:RNA) insider Teresa Mccarthy sold 1,965 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $72.23, for a total transaction of $141,931.95. Following the completion of the sale, the insider owned 116,867 shares of the company’s stock, valued at $8,441,303.41. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Teresa Mccarthy also recently made the following trade(s):

• On Wednesday, October 15th, Teresa Mccarthy sold 20,000 shares of Avidity Biosciences stock. The stock was sold at an average price of $50.15, for a total value of $1,003,000.00.

Avidity Biosciences Price Performance

Shares of RNA stock opened at $72.37 on Friday. The business’s fifty day moving average is $71.41 and its 200 day moving average is $52.73. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of -17.31 and a beta of 0.95. Avidity Biosciences, Inc. has a twelve month low of $21.51 and a twelve month high of $72.61.

Avidity Biosciences (NASDAQ:RNA) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.22). Avidity Biosciences had a negative return on equity of 37.70% and a negative net margin of 2,634.59%.The business had revenue of $12.48 million for the quarter, compared to the consensus estimate of $1.80 million. Avidity Biosciences’s quarterly revenue was up 420.8% compared to the same quarter last year. Equities research analysts expect that Avidity Biosciences, Inc. will post -2.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avidity Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in RNA. Allworth Financial LP grew its position in Avidity Biosciences by 22.8% during the third quarter. Allworth Financial LP now owns 856 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 159 shares during the period. Fort Point Capital Partners LLC raised its holdings in Avidity Biosciences by 0.6% during the third quarter. Fort Point Capital Partners LLC now owns 31,278 shares of the biotechnology company’s stock valued at $1,363,000 after acquiring an additional 183 shares during the period. GAMMA Investing LLC raised its stake in Avidity Biosciences by 10.5% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 234 shares during the period. AlphaQuest LLC lifted its holdings in shares of Avidity Biosciences by 123.0% in the third quarter. AlphaQuest LLC now owns 600 shares of the biotechnology company’s stock worth $26,000 after buying an additional 331 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in Avidity Biosciences by 0.5% in the 2nd quarter. California State Teachers Retirement System now owns 90,258 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 466 shares in the last quarter.

Trending Headlines about Avidity Biosciences

Here are the key news stories impacting Avidity Biosciences this week:

• Neutral Sentiment: W. Michael Flanagan sold 2,373 shares (~$171.4k), reducing his stake ~2.52%. SEC filing – Flanagan sale
• Neutral Sentiment: Michael F. Maclean (CFO) sold 1,974 shares (~$142.6k), a ~3.00% decrease in his ownership. SEC filing – Maclean sale
• Neutral Sentiment: Teresa McCarthy sold 1,965 shares (~$141.9k), reducing her stake ~1.65%. SEC filing – McCarthy sale
• Negative Sentiment: Steven George Hughes sold 2,373 shares (~$171.4k), a ~6.11% reduction in his position — larger proportional sale that may draw investor scrutiny. SEC filing – Hughes sale
• Negative Sentiment: John B. Moriarty sold 2,374 shares (~$171.5k), a ~3.09% drop in his holdings. SEC filing – Moriarty sale
• Negative Sentiment: Charles Calderaro III sold 3,727 shares (~$269.2k), a ~6.96% reduction — one of the larger proportional sales among insiders. SEC filing – Calderaro sale
• Negative Sentiment: CEO Sarah Boyce sold 8,576 shares (~$619.4k), reducing her stake ~2.94%; CEO sales tend to attract investor attention despite modest percentage change. SEC filing – Boyce sale

Wall Street Analysts Forecast Growth

RNA has been the subject of a number of recent analyst reports. Cowen restated a “hold” rating on shares of Avidity Biosciences in a report on Wednesday, November 12th. Sanford C. Bernstein cut Avidity Biosciences from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $52.00 to $72.00 in a research note on Monday, October 27th. Wolfe Research cut Avidity Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Chardan Capital reissued a “neutral” rating and issued a $72.00 target price on shares of Avidity Biosciences in a research report on Tuesday, November 11th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $72.00 price target (up previously from $65.00) on shares of Avidity Biosciences in a report on Monday, October 27th. Eight investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $69.57.

About Avidity Biosciences

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.